REG - Tissue Regenix Group - Board Changes

Tissue RegenixAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250908:nRSH2934Ya&default-theme=true

RNS Number : 2934Y  Tissue Regenix Group PLC  08 September 2025

 Tissue Regenix Group plc

('Tissue Regenix' or 'the Group')

 

Board Changes

Jay LeCoque appointed as Executive Chairman

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces
the following changes to its Board of Directors.

 

Jay LeCoque will join the Board of Tissue Regenix as Executive Chairman,
effective from today. Jay brings extensive experience from his role as
Executive Chairman of Source BioScience Limited, Commercial Director of
Bioquell PLC, and CEO of Celsis International PLC and Limited. He has over 25
years of senior management experience in the global business development of UK
listed and privately held life sciences companies. 

 

Jonathan Glenn, Chairman, and Trevor Phillips, Non-Executive Director, have
both resigned from the Board, effective from today. The Company thanks both
Jonathan and Trevor for their dedication and valuable contributions during
their time on the Board.

 

Daniel Lee, CEO of Tissue Regenix, commented: "On behalf of the Board, I would
like to thank Jonathan and Trevor for their commitment and support to the
Company over the years. They have each made valued contributions to the Group
and I wish them all the best in their future endeavours.

 

"We are pleased to appoint Jay LeCoque as Executive Chairman. His extensive
knowledge and experience in the global healthcare and the clinical life
sciences sector will contribute greatly to the business as we continue to grow
and strengthen earnings to meet our long-term objectives."

 

Additional disclosures required under Rule 17 and Schedule Two paragraph (g)
of the AIM Rules for Companies

Jay Charles LeCoque, aged 62, has held the following directorships or
partnerships in the past five years:

 

 Current Directorships                      Previous Directorships (within the past five years)
 Cryobank Guarantor Limited                 Source Bioscience (Storage) Limited
 Fairfield Telepathology Limited            Source Bioscience (Healthcare) Limited
 Source Bioscience (Cryobank) Limited       Geneservice Limited
 Source Bioscience (Orchard Place) Limited  Quinoderm Limited
 Kinetic Imaging Limited                    Select Storage Solutions (Scotland) Ltd
 Fairfield Imaging Limited                  Medical Solutions (Leeds) Limited
 Source Bioscience Scotland Limited
 Source Bioscience Uk Limited
 Select Pharma Laboratories Ltd
 Sourcebio International Limited
 Source Bioscience Limited
 LDPath Limited
 Source Genomics Limited
 Cambridge Clinical Laboratories Ltd
 Rivage Ventures LLC

 

Mr LeCoque and persons closely associated (as defined under MAR) with Mr
LeCoque do not currently hold any shares in the Company.

 

Save as disclosed above, there is no further information to be disclosed in
respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph
(g) of the AIM Rules for Companies.

 

For more information:

 

 Tissue Regenix Group plc                                           www.tissueregenix.com (http://www.tissueregenix.com)
 Daniel Lee, Chief Executive Officer                                via Walbrook PR

 Brandon Largent, Interim Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                             Tel: +44 (0) 20 7466 5000
 Nigel Birks - Life Science Specialist Sales
 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                                  Tel: +44 (0)20 7933 8780
 Alice Woodings                                                     TissueRegenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASSSFMIEISEIU